Biogened S.A. produces and sells cosmetics and toiletries in Poland. The company offers dermo-cosmetics under the Dermedic brand, as well as thermal water. It also exports its products. The company was incorporated in 2007 and is headquartered in Lódz, Poland.…
Biogened (BGD) - Finanse - wyniki finansowe
Biogened (WSE: BGD) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 186 employees.
The shares were at 19.70 PLN on 20 November 2026, down 15.8% over 52 weeks. Its 52-week range is 17.30 PLN to 25.60 PLN: the price is 23.0% below the high and 13.9% above the low.
At a market capitalisation of 48.39M PLN, it trades at 10.1 times trailing earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a discount of 59% for BGD. It pays a dividend yielding 2.53% (it pays out 24% of its earnings), against a median of 1.95% among the dividend payers in that peer group.
Biogened reports return on equity of 11.0%, an operating margin of 7.4% and revenue up 5.3% year over year.
Its debt exceeds its cash by 18.75M PLN, a debt-to-equity ratio of 0.51. Its Piotroski F-score is 6 out of 9, an average reading of its financial health.
No upcoming events tracked.